

DAFTAR PUSTAKA

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020 Feb 20;382(8):727–33.
2. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. *N Engl J Med*. 2020 Jun 18;382(25):102.
3. WHO (2021). Coronavirus disease (COVID-19) situation reports. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports> - Diakses Desember 2021.
4. WHO Indonesia (2021). Situation reports. <https://www.who.int/indonesia/news/novelcoronavirus/situation-reports> – Diakses Desember 2021.
5. Provinsi Sumatera Barat (2021). Data pantauan COVID-19. <https://corona.sumbarprov.go.id/> – Diakses Desember 2021.
6. Perhimpunan Dokter Paru Indonesia. Pneumonia COVID-19 diagnosis & penatalaksanaan di Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia; 2020.
7. Id NP, van de Maat Id J, Veerman K, ten Oever J, Janssenid N, Abbink E, et al. Clinical characteristics and outcomes of 952 hospitalized COVID-19 patients in The Netherlands: A retrospective cohort study. 2021; 16(3):248.
8. Cunningham JW, Vaduganathan M, Claggett BL, Jering KS, Bhatt AS, Rosenthal N, et al. Clinical outcomes in young US adults hospitalized with COVID-19. *JAMA Internal Medicine*. 2021 Mar 1;181(3):379–81.
9. Oliveira E, Parikh A, Lopez-Ruiz A, Carrilo M, Goldberg J, Cearras M, et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. *PLoS OnE*. 2021 Mar 1;16.
10. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *J Med Virol*. 2020 Sep 1;92(9):1518–24.
11. Kementerian Kesehatan Republik Indonesia (2020). 13,2 persen pasien covid-19 yang meninggal memiliki penyakit hipertensi. <https://www.kemkes.go.id/article/print/20101400002/13-2-persen-pasien-covid-19-yang-meninggal-memiliki-penyakit-hipertensi.html>. – Diakses Januari 2022
12. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. The JNC 8 hypertension guidelines: An in-depth guide. *JAMA*. 2014 Feb 5. 311(5):507–20.
13. Direktorat Pencegahan dan Pengendalian Penyakit Tidak Menular (2019). Hari hipertensi dunia 2019: “Know your number, kendalikan tekanan darahmu dengan CERDIK.”. <http://p2ptm.kemkes.go.id/kegiatan-p2ptm/pusat/hari-hipertensi-dunia-2019-know-your-number-kendalikan-tekanan-darahmu-dengan-cerdik>. – Diakses Januari 2022.
14. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. *N Engl J Med*. 2020 Apr 23;382(17):1653–9.
15. Kementerian Koordinator Bidang Pembangunan Manusia dan Kebudayaan (2021). Hipertensi komorbid tertinggi Covid-19.

- <https://www.kemendiknas.go.id/hipertensi-komorbid-tertinggi-covid-19>. – Diakses Desember 2021.
16. Sylvestris A. Hipertensi dan retinopati hipertensi. *Saintika Medika*. 2014 Mar 20;10(1):1–9.
 17. WHO (2020). Clinical management of COVID-19: interim guidance, 27 May 2020. <https://apps.who.int/iris/handle/10665/332196> - Diakses Februari 2022.
 18. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020 Apr 30;382(18):1708–20.
 19. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. *JAMA*. 2020 Mar 17;323(11):1061.
 20. Zhang J jin, Dong X, Cao Y yuan, Yuan Y dong, Yang Y bin, Yan Y qin, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020 Jul 1;75(7):1730–41.
 21. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 outbreak in China: Summary of a report of 72 314 cases from the chinese center for disease control and prevention. *JAMA*. 2020 Apr 7;323(13):1239–42.
 22. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. *Methods in molecular biology* (Clifton, NJ). 2015 Feb;1282:1–23.
 23. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* (London, England). 2020 Feb 15;395(10223):497–506.
 24. Wuhan WQ, Yongxi Z, Siyang C, Xiaomao J. A handbook of 2019-nCoV pneumonia control and prevention. Hubei: Hubei Science and Technology Press;2020.
 25. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *J Adv Res*. 2020 Jul 1;24:91–8.
 26. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. *Virol J*. 2019 May 27;16(1).
 27. Jalava K. First respiratory transmitted food borne outbreak. *Int J Hyg Environ Health*. 2020 May 1;226.
 28. Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. *J Hosp Infect*. 2016 Mar 1;92(3):235–50.
 29. WHO (2020). Transmission of SARS-CoV-2: implications for infection prevention precautions. <https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions> - Diakses Februari 2022.
 30. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. *Gastroenterology*. 2020 May 1;158(6):1831.

31. Sun J, Zhu A, Li H, Zheng K, Zhuang Z, Chen Z, et al. Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. *Emerg Microbes Infect.* 2020 Jan 1;9(1):991–3.
32. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. *N Engl J Med.* 2020 Apr 16;382(16):1564–7.
33. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. *Ann Intern Med.* 2020 May 5;172(9):577–82.
34. CDC (2021). Symptoms of COVID-19. <https://www.Cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html> - Diakses Februari 2022
35. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N Engl J Med.* 2020 Mar 19;382(12):1177–9.
36. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect Dis.* 2020 Jun 1;20(6):656–7.
37. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet.* 2020 Feb 22;395(10224):565.
38. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol.* 2004 Jun;203(2):631–7.
39. Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, Pickles RJ. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. *J Virol.* 2005 Dec 15;79(24):15511–24.
40. Sungnak W, Huang N, Bécavin C, Berg M, Network HLB. SARS-CoV-2 entry genes are most highly expressed in nasal goblet and ciliated cells within human airways. *ArXiv.* 2020 Mar 13;
41. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci.* 2020 Dec 1;12(1).
42. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. *J Clin Immunol.* 2020 May 1;214.
43. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. *Curr Biol.* 2020 Apr 6;30(7):1346–1351.
44. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. *Nat Rev Microbiol.* 2016 Aug 1;14(8):523–34.

45. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. *J Med Virol*. 2020 Apr 1;92(4):424.
46. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. *J Pharm Anal*. 2020 Apr 1;10(2):102–8.
47. Chatterjee SK, Saha S, Munoz MNM. Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19. *Front Mol Biosci*. 2020 Aug 11;7:196.
48. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: A cross-sectional study. *Infectious Disease Society America*. 2020 Aug 1;71(15):889–90.
49. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. *Circulation*. 2020 May 19;141:1648–55.
50. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis*. 2020 Apr 1;20(4):425–34.
51. Burhan E, Dwi Susanto A, Isbaniah F, Aman Nasution S, Ginanjar E, Wicaksono Pitoyo C, editors. *Pedoman tatalaksana COVID-19 edisi 3*. Jakarta;2020.
52. WHO (2020). Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance, 19 March 2020. <https://apps.who.int/iris/handle/10665/331501>- Diakses Februari 2022.
53. Kementerian Kesehatan Republik Indonesia (2021). *Manajemen klinis tata laksana corona virus disease 2019 (covid-19) di fasilitas pelayanan Kesehatan*. <https://covid19.go.id/storage/app/media/Regulasi/2021/Agustus/kmk-no-hk0107-menkes-5671-2021-ttg-manajemen-klinis-tata-laksana-covid-19-di-fasilitas-pelayanan-kesehatan-signed-1.pdf> - Diakses Februari 2022.
54. Vincent JL. COVID-19: it is all about sepsis. *Future Microbiol*. 2021 Feb 1;16(3):131–3.
55. da Silva Ramos FJ, de Freitas FGR, Machado FR. Sepsis in patients hospitalized with coronavirus disease 2019: how often and how severe? *Current Opinion in Critical Care*. 2021 Oct ;27(5):474.
56. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018 Sep 1;39(33):3021–104.
57. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International society of hypertension global hypertension practice guidelines. *Am Heart J*. 2020 Jun 1;75(6):1334–57.
58. Kementerian Kesehatan Republik Indonesia (2019). *Hipertensi penyakit paling banyak diidap masyarakat*. <https://www.kemkes.go.id/article/view/19051700002/hipertensi-penyakit-paling-banyak-diidap-masyarakat.html> – Diakses Februari 2022.
59. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. *JAMA*. 2013 Sep 4;310(9):959–68.

60. WHO (2021). Hypertension. <https://www.who.int/news-room/fact-sheets/detail/hypertension> - Diakses Februari 2022.
61. Kasper DL, Braunwald E, Hauser S, Longo, Jameson JL, Fauci AS. Harrison's principles of international medicine. The McGraw-Hill Companies;2005. hlm. 1653.
62. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. *Lancet Respir Med.* 2020 Apr 1;8(4):21.
63. South AM, Brady TM, Flynn JT. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE inhibitor and ang II (angiotensin II) receptor blocker use during the pandemic: the pediatric perspective. *J Am Heart Assoc.* 2020 Jul 1;76(1):16–22.
64. Simões e Silva AC, Flynn JT. The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease. *Pediatr Nephrol.* 2012 Oct;27(10):1835–45.
65. South AM, Shaltout HA, Washburn LK, Hendricks AS, Diz DI, Chappell MC. Fetal programming and the angiotensin-(1–7) axis: a review of the experimental and clinical data. *Clin Sci.* 2019 Jan 1;133(1):55.
66. Sampaio WO, dos Santos RAS, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. *Am Heart J.* 2007 Jan;49(1):185–92.
67. Yousif MHM, Benter IF, Diz DI, Chappell MC. Angiotensin-(1–7)-dependent vasorelaxation of the renal artery exhibits unique angiotensin and bradykinin receptor selectivity. *Peptides.* 2017 Apr 1;90:10.
68. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. *Am J Hypertens.* 2020 Apr 29;33(5):373–4.
69. Suharsimi A. *Prosedur penelitian: suatu pendekatan praktek.* Jakarta: Rineka Cipta;2006.
70. Sugiyono. *Metode penelitian kuantitatif, kualitatif, dan R&D.* Yogyakarta: Alfabeta;2012.
71. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. *Infect Dis Poverty.* 2020 Mar 17;9(1).
72. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ.* 2020 Feb 19;368:m606–m606.
73. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020 Mar 28;395(10229):1054–62.
74. Bonanad C, García-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-González V, Fácila L, et al. The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. *J Am Med Dir Assoc.* 2020 Jul 1;21(7):915–8.
75. Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and clinical characteristics of COVID-19. *Arch Iran Med.* 2020;23(4):268–71.

76. Samrah SM, Al-Mistarehi AH, Kewan T, Al-Khatib SM, Ibnian AM, Samrah RS, et al. Viral clearance course of COVID-19 outbreaks. *J Multidiscip Healthc.* 2021;14:555.
77. Chen X, Hu MT W, Yang M, Ling J, Zhang Y, Deng L, et al. Risk factors for the delayed viral clearance in COVID-19 patients. *The Journal of Clinical Hypertension.* 2021 Aug 1;23(8):1483.
78. Hu X, Xing Y, Jia J, Ni W, Liang J, Zhao D, et al. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. *Sci Total Environ.* 2020 Aug 1;728.
79. Chen X, Zhu B, Hong W, Zeng J, He X, Chen J, et al. Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. *Int J Infect Dis.* 2020 Jun 30;98:252–60.
80. Wang S, Zhang Q, Wang P, Ye H, Jing X, Zhang Z, et al. Clinical features of hypertensive patients with COVID-19 compared with a normotensive group: single-center experience in China. *Open Medicine.* 2021 Jan 1;16(1):367.
81. Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable?. *Biol Sex Differ.* 2020 Sep 18;11(1).
82. Chen J, Jiang Q, Xia X, Liu K, Yu Z, Tao W, et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. *Aging Cell.* 2020 Jul 1;19(7).
83. Kamyshnyi A, Krynytska I, Matskevych V, Marushchak M, Lushchak O. Arterial hypertension as a risk comorbidity associated with COVID-19 pathology. *Int J Hypertens.* 2020;2020.
84. Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. Status of hypertension in china: results from the china hypertension survey, 2012-2015. *Circulation.* 2018;137(22):2344–56.
85. Mphekgwana PM, Matlala SF, Tshitangano TG, Ramalivhana NJ, Sono-Setati ME. Risk Factors for hypertension in hospitalised Patient mortality with laboratory-confirmed SARS-CoV-2: a population-based study in limpopo province, south africa. *Journal of Respiration.* 2022 Sep 5 [;2(3):147–56.
86. SeyedAlinaghi SA, Abbasian L, Solduzian M, Ayoobi Yazdi N, Jafari F, Adibimehr A, et al. Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study. *Eur J Med Res.* 2021 Dec 1;26(1):1–10.
87. Xue J, Zheng J, Shang X, Qin E, Zhao P, He Y, et al. Risk factors for prolonged viral clearance in adult patients with COVID-19 in beijing, china: a prospective observational study. *Int Immunopharmacol.* 2020 Dec 1;89.
88. Chen X, Hu W, Ling J, Mo P, Zhang Y, Jiang Q, et al. Hypertension and diabetes delay the viral clearance in COVID-19 patients. *medRxiv.* 2020 Mar 24.
89. Hoffman EN, Kawachi H, Hirayama A, Zhang J, Murayama A, Masui J, et al. Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in osaka, japan. *Environ Health Prev Med.* 2021 Dec 1;26(1):1–11.

90. Abraham SA, Tessema M, Defar A, Hussen A, Ejeta E, Demoz G, et al. Time to recovery and its predictors among adults hospitalized with COVID-19: a prospective cohort study in ethiopia. *PLoS One*. 2020 Dec 1;15(12):e0244269.
91. Trump S, Lukassen S, Anker MS, Chua RL, Liebig J, Thürmann L, et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. *Nature Biotechnology*. 2020 Dec 24;39(6):705–16.
92. Wei CJ, Hu XX, Ye GM, Yang JM, Cheng ZS, Wang XH. Time and risk factors of viral clearance in COVID-19 patients. *Chin Med J (Engl)*. 2021 Sep 9;134(17):2131.
93. Zhong L, Wu Y, Gao J, Zhang J, Xie Q, He H, et al. Effects of hypertension on the outcomes of COVID-19: a multicentre retrospective cohort study. *Ann Med*. 2021;53(1):770.
94. Faustine I, Malik A, Andrajati R, Wanandi SI. Clinical characteristics and severity profile of COVID-19 patient with hypertension in palu, central sulawesi. *Indonesian Journal of Pharmacy*. 2021 Oct 1;32(4):563–72.
95. Zhong L, Wu Y, Gao J, Zhang J, Xie Q, He H, et al. Effects of hypertension on the outcomes of COVID-19: a multicentre retrospective cohort study. *Ann Med*. 2021;53(1):770.
96. Fresán U, Guevara M, Trobajo-Sanmartín C, Burgui C, Ezpeleta C, Castilla J. Hypertension and related comorbidities as potential risk factors for COVID-19 hospitalization and severity: a prospective population-based cohort study. *J Clin Med*. 2021 Mar 2;10(6):1–12.

